Fulgent Genetics, Inc.
Fulgent Genetics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 26 | 23 | 50 | 118 | 88 | 67 | 55 | 58 | 65 | 55 | 97 | 84 | |||||
Available For Sale Securities Debt Securities Curr… | 231 | 253 | 286 | - | - | - | 203 | - | - | - | - | - | |||||
Accounts Receivable Net Current | 65 | 69 | 85 | 71 | 77 | 71 | 69 | 57 | 57 | 52 | 51 | 49 | |||||
Prepaid Taxes | 111 | 109 | 107 | - | - | - | 3 | - | - | - | - | - | |||||
Other Assets Current | 22 | 24 | 23 | 60 | 59 | 25 | 23 | 56 | 31 | 29 | 33 | 33 | |||||
Assets Current | 455 | 479 | 550 | 507 | 429 | 417 | 354 | 327 | 399 | 387 | 508 | 550 | |||||
Intangible Assets Net Excluding Goodwill | - | 154 | 133 | 135 | 131 | 133 | 135 | 137 | 139 | 141 | 143 | 144 | |||||
Available For Sale Securities Debt Securities Nonc… | 294 | 328 | 369 | 412 | 484 | 494 | 570 | 602 | 526 | 540 | 424 | 384 | |||||
Property Plant And Equipment Net | 113 | 116 | 113 | 112 | 110 | 107 | 106 | 107 | 93 | 87 | 83 | 85 | |||||
Indefinite Lived Intangible Assets Excluding Goodw… | 68 | 68 | 68 | - | - | - | 65 | - | - | - | - | - | |||||
Other Intangible Assets Net | 81 | 85 | 65 | - | - | - | 70 | - | - | - | - | - | |||||
Goodwill | 54 | 54 | 25 | 25 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 142 | |||||
Other Assets Noncurrent | 24 | 25 | 23 | 23 | 23 | 33 | 33 | 39 | 32 | 33 | 35 | 38 | |||||
Assets | 1,089 | 1,156 | 1,214 | 1,215 | 1,200 | 1,206 | 1,220 | 1,234 | 1,232 | 1,230 | 1,235 | 1,358 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 16 | 21 | 19 | 18 | 19 | 18 | 18 | 20 | 20 | 20 | 15 | 16 | |||||
Accrued Liabilities Current | 24 | 35 | 34 | 23 | 22 | 17 | 24 | 24 | 26 | 26 | 31 | 21 | |||||
Contract With Customer Liability Current | 3 | 3 | 4 | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | |||||
Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | |||||
Other Liabilities Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Liabilities Current | 72 | 90 | 85 | 72 | 71 | 66 | 73 | 74 | 76 | 76 | 73 | 61 | |||||
Deferred Income Tax Liabilities Net | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 10 | |||||
Unrecognized Tax Benefits | 6 | 6 | 7 | 7 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 10 | |||||
Other Liabilities Noncurrent | 9 | 9 | 8 | 8 | 6 | 6 | 7 | 12 | 14 | 14 | 15 | 16 | |||||
Liabilities | 93 | 112 | 107 | 94 | 88 | 83 | 91 | 99 | 103 | 103 | 102 | 97 | |||||
Stockholders Equity Inclu… | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital Common Stock | 524 | 540 | 575 | 566 | 551 | 544 | 543 | 533 | 522 | 511 | 502 | 514 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 2 | 5 | 8 | 7 | 6 | 4 | -0 | 9 | -1 | -1 | 1 | -17 | |||||
Retained Earnings Accumulated Deficit | 476 | 505 | 530 | 553 | 560 | 579 | 590 | 596 | 611 | 620 | 633 | 761 | |||||
Stockholders Equity | 1,002 | 1,044 | 1,112 | 1,121 | 1,112 | 1,127 | 1,129 | 1,135 | 1,129 | 1,127 | 1,136 | 1,262 | |||||
Minority Interest | -6 | -6 | -5 | -5 | -5 | -4 | -4 | -4 | -4 | -3 | -3 | 3 | |||||
Liabilities And Stockholders Equity | 1,089 | 1,156 | 1,214 | 1,215 | 1,200 | 1,206 | 1,220 | 1,234 | 1,232 | 1,230 | 1,235 | 1,358 | |||||
Allowance For Doubtful Accounts Receivable | 26 | 21 | 21 | 22 | 21 | 21 | 20 | 25 | 25 | 26 | 25 | 29 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | |||||
Common Stock Shares Issued | 35 | 35 | 35 | 34 | 34 | 34 | 34 | 33 | 33 | 33 | 32 | 32 | |||||
Shares Outstanding | 28 | 29 | 31 | 31 | 31 | 31 | 31 | 31 | 30 | 30 | 30 | 30 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.09% | 27.39% | 42.68% | - | - | - | - | - | - | - | - | - |
| 2025 | -1.12% | -4.92% | -13.44% | 17.49% | 20.45% | 22.40% | 12.22% | 1.37% | 5.54% | 1.17% | 6.07% | 2.41% |
| 2024 | -0.51% | -5.72% | 1.49% | -5.03% | -12.29% | -21.15% | -5.82% | -5.46% | -11.43% | 10.61% | 15.60% | 31.72% |
| 2023 | - | - | - | -13.46% | -29.74% | -34.65% | 3.67% | 12.21% | -2.82% | -6.81% | -13.01% | -5.53% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 6.34 | 5.31 | 6.48 | 7.01 | 6.01 | 6.32 | 4.85 | 4.41 | 5.27 | 5.09 | 6.96 | 8.95 | |||||
| Quick Ratio | 6.34 | 5.31 | 6.48 | 7.01 | 6.01 | 6.32 | 4.85 | 4.41 | 5.27 | 5.09 | 6.96 | 8.95 | |||||
| Working Capital | 383.01M | 388.91M | 465.52M | 434.95M | 357.39M | 350.87M | 280.67M | 252.55M | 323.35M | 310.56M | 434.83M | 488.43M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.09 | 0.11 | 0.10 | 0.08 | 0.08 | 0.07 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | |||||
| Interest Coverage TTM | -1,019.03 | -1,357.99 | -1,214.61 | -717.10 | -855.55 | -773.28 | -225.36 | -295.90 | -251.46 | -261.20 | -400.67 | -1,156.57 | |||||
| Debt Ratio | 0.09 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.28 | 0.27 | 0.27 | 0.26 | 0.25 | 0.24 | 0.23 | 0.21 | 0.22 | 0.22 | 0.22 | 0.21 | |||||
| Days Sales Outstanding TTM | 80.07 | 80.19 | 86.98 | 74.32 | 80.51 | 77.09 | 77.36 | 70.04 | 57.37 | 60.68 | 65.55 | 97.77 | |||||
| Receivables Turnover TTM | 4.56 | 4.55 | 4.20 | 4.91 | 4.53 | 4.73 | 4.72 | 5.21 | 6.36 | 6.01 | 5.57 | 3.73 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -3.08 | -2.44 | -2.00 | -1.39 | -1.66 | -1.32 | -1.41 | -5.66 | -5.67 | -5.81 | -5.88 | -2.11 | |||||
| Free Cash Flow Per Share TTM | -3.71 | -3.66 | -4.04 | -0.65 | -1.96 | -1.03 | -0.64 | -0.94 | 0.39 | 0.60 | 0.16 | 0.71 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 35.58% | 38.71% | 40.56% | 41.24% | 40.04% | 38.80% | 37.82% | 36.22% | 39.10% | 37.47% | 36.12% | 32.20% | |||||
| Operating Profit Margin TTM | -37.75% | -33.07% | -28.23% | -22.50% | -23.98% | -24.59% | -26.08% | -75.21% | -65.91% | -66.95% | -67.61% | -28.27% | |||||
| Net Profit Margin TTM | -26.59% | -23.53% | -19.10% | -13.57% | -16.70% | -13.94% | -15.07% | -62.02% | -58.72% | -60.12% | -60.59% | -22.07% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | 6.83% | 9.54% | 13.83% | 13.60% | 4.31% | 1.71% | -1.99% | -3.02% | -5.42% | -21.20% | -53.27% | -64.33% | |||||
| Net Income Growth (1Y) | 70.09% | 84.85% | 44.31% | -75.14% | -70.33% | -76.41% | -75.63% | 172.47% | 250.04% | 564.74% | -222.20% | -123.43% | |||||
| EPS Growth (1Y) | 85.51% | 84.56% | 41.77% | -75.41% | -70.77% | -77.22% | -75.99% | 168.86% | 246.73% | 559.54% | -223.48% | -123.56% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -6.67 | -6.51 | -13.12 | -16.23 | -11.99 | -12.78 | -13.08 | -3.84 | -3.46 | -3.74 | -4.91 | -12.69 | |||||
| P/B TTM | 0.57 | 0.47 | 0.73 | 0.62 | 0.55 | 0.46 | 0.49 | 0.58 | 0.52 | 0.57 | 0.76 | 0.64 | |||||
| P/S TTM | 1.77 | 1.53 | 2.51 | 2.20 | 2.00 | 1.78 | 1.97 | 2.38 | 2.03 | 2.25 | 2.98 | 2.80 | |||||
| Market Cap | 574.66M | 491.01M | 808.51M | 694.93M | 607.21M | 521.06M | 558.44M | 660.94M | 590.52M | 645.99M | 861.06M | 802.55M | |||||
| Enterprise Value | 548.70M | 467.96M | 758.66M | 577.63M | 519.68M | 454.12M | 503.71M | 603.17M | 525.82M | 591.72M | 764.77M | 721.36M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -103.79M | -113.17M | -124.21M | -19.85M | -59.95M | -31.61M | -19.26M | -28.67M | 11.70M | 17.95M | 4.80M | 21.45M | |||||
| Net Debt | -25.96M | -23.05M | -49.85M | -117.30M | -87.54M | -66.94M | -54.73M | -57.77M | -64.70M | -54.26M | -96.29M | -81.19M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Fulgent Genetics, Inc. (FLGT) — SEC Financial Statements & Analysis
Fulgent Genetics, Inc. (FLGT) is a services-medical laboratories company, incorporated in DE. Fulgent Genetics, Inc. trades on Nasdaq as: FLGT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Fulgent Genetics, Inc. reported a 6.83% year-over-year revenue growth, a Gross Profit Margin of 35.58% (TTM), a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 1.77x (TTM), a Price-to-Book (P/B) ratio of 0.57x (TTM), at a market cap of $574.66M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 6.83%
- Gross Profit Margin TTM
- 35.58%
- Debt To Equity
- 0.09x
- P/S TTM
- 1.77x
- P/B TTM
- 0.57x
- Market Cap
- $574.66M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Fulgent Genetics, Inc. in?
Fulgent Genetics, Inc. (FLGT) operates in the Services-Medical Laboratories industry.
What is FLGT's market cap?
Fulgent Genetics, Inc. (FLGT) has a market capitalization of $574.66M as of 2026-06-30.
What exchange does FLGT trade on?
Fulgent Genetics, Inc. (FLGT) trades on the Nasdaq.
Where is Fulgent Genetics, Inc. incorporated?
Fulgent Genetics, Inc. is incorporated in DE.